The volume-weighted average price manufacturers actually realise for a drug, net of most discounts and rebates, reported quarterly to CMS.
ASP is the basis for Medicare Part B drug payment. Because it is reported with a two-quarter lag, the rate in force today reflects market prices from roughly six months ago — which is why a drug whose price has just risen can be reimbursed below acquisition cost.